Dark Arrow icon
Home

StratifAI Achieves International Data Security and Privacy Certifications for Polaris™, Its AI Multimodal Biomarker Discovery Platform

The milestone strengthens the security and governance foundation of Polaris™, supporting its use within regulated healthcare and life sciences environments in EU and US.

Berlin, Germany — January 2026 — StratifAI, the precision oncology company advancing cancer diagnostics through AI-driven biomarkers, has achieved ISO 27001 and ISO 27701 certifications, successfully completed a SOC 2 Type II audit and maintains full GDPR and HIPAA compliance for its multimodal biomarker discovery platform, Polaris™.

These certifications underline that Polaris™ meets internationally recognized requirements for information security management, privacy protection, and operational controls, providing a robust foundation for the responsible use of AI in healthcare.

Enabling secure adoption of AI in healthcare

As AI technologies are increasingly adopted across research and clinical development workflows, expectations around security, governance, and technical robustness continue to rise. StratifAI is holding Polaris™ to the highest internationally recognized standards for data security and privacy to support responsible implementation of AI in healthcare environments.

With independently audited controls in place, Polaris™ enables technically safe and well-governed use of AI in workflows involving sensitive clinical data, supporting biomarker discovery and research within established regulatory and institutional frameworks.

"Achieving these internationally recognized security standards reflects StratifAI’s unwavering commitment to quality. This enables us to deliver the AI infrastructure required to accelerate the discovery of next-generation multimodal cancer biomarkers and scale AI adoption with our trusted partners across the healthcare and life sciences industry.”
Omar El Nahhas
CEO & Co-Founder at StratifAI

A foundation for global collaboration

This foundation enables StratifAI to scale its partnerships internationally. Hospitals, academic centers, and life sciences organizations can engage with Polaris™ platform with consistent safeguards across data access, processing, and use. As StratifAI continues to expand, these milestones support broader collaboration and long-term adoption of Polaris™.

Contact information

For media inquiries, please contact:

Meri Khazaradze
press@stratifai.com

About StratifAI

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Its discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers.

Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, helping refine adjuvant treatment options. Retrospectively validated on thousands of patients from Phase III trials and in real-world clinical settings, Polaris™ Breast is available for research-use only and is undergoing regulatory approval in the EU and US.

For more information, visit www.stratifai.com